Abstract:Background/Objectives: Human epidermal growth factor receptor 2 (HER2) is overexpressed in several malignancies, such as breast, gastric, ovarian, and lung cancers, where it promotes aggressive tumor proliferation and unfavorable prognosis. Targeting HER2 has thus emerged as a crucial therapeutic strategy, particularly for HER2-positive malignancies. The present study focusses on the design and optimization of peptide inhibitors targeting HER2, utilizing machine learning to identify and enhance peptide candidates with elevated binding affinities. The aim is to provide novel therapeutic options for malignancies linked to HER2 overexpression. Methods: This study started with the extraction and structural examination of the HER2 protein, succeeded by designing the peptide sequences derived from essential interaction residues. A machine learning technique (XGBRegressor model) was employed to predict binding affinities, identifying the top 20 peptide possibilities. The candidates underwent further screening via the FreeSASA methodology and binding free energy calculations, resulting in the selection of four primary candidates (pep-17, pep-7, pep-2, and pep-15). Density functional theory (DFT) calculations were utilized to evaluate molecular and reactivity characteristics, while molecular dynamics simulations were performed to investigate inhibitory mechanisms and selectivity effects. Advanced computational methods, such as QM/MM simulations, offered more understanding of peptide–protein interactions. Results: Among the four principal peptides, pep-7 exhibited the most elevated DFT values (−3386.93 kcal/mol) and the maximum dipole moment (10,761.58 Debye), whereas pep-17 had the lowest DFT value (−5788.49 kcal/mol) and the minimal dipole moment (2654.25 Debye). Molecular dynamics simulations indicated that pep-7 had a steady binding free energy of −12.88 kcal/mol and consistently bound inside the HER2 pocket during a 300 ns simulation. The QM/MM simulations showed that the overall total energy of the system, which combines both QM and MM contributions, remained around −79,000 ± 400 kcal/mol, suggesting that the entire protein–peptide complex was in a stable state, with pep-7 maintaining a strong, well-integrated binding. Conclusions: Pep-7 emerged as the most promising therapeutic peptide, displaying strong binding stability, favorable binding free energy, and molecular stability in HER2-overexpressing cancer models. These findings suggest pep-7 as a viable therapeutic candidate for HER2-positive cancers, offering a potential novel treatment strategy against HER2-driven malignancies.

Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging.

Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor.

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.

Her2 Targeting Peptides Screening And Applications In Tumor Imaging And Drug Delivery

Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99m Tc-HYNIC-H10F

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Synergetic Tumor Probes for Facilitating Therapeutic Delivery by Combined-Functionalized Peptide Ligands

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors

Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer

Optical Biosensor Based on Weak Value Amplification for the High Sensitivity Detection of Pertuzumab in Combination with Trastuzumab Binding to the Extracellular Domain of HER2.

In Silico Design of Peptide Inhibitors Targeting HER2 for Lung Cancer Therapy

Evaluation of 177Lu-Labeled Pertuzumab F(ab′)2 Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study

Targeting HER2-positive Gastric Cancer with a Novel 18F-Labeled ZHER2:342 Probe

An amplification strategy for detecting HER2 with a quasi-targeted proteomics approach coupled with aptamer-triggered hybridization chain reaction

Developing PEGylated Reversed D-Peptide As a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection

A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.

Radiolabeled Pertuzumab for Imaging of Human Epidermal Growth Factor Receptor 2 Expression in Ovarian Cancer.

Tracing Investigation of Targeting Gastric Cancer with 18F Labeled Anti-Human Epidermal Growth Factor Receptor 2 Specific Affibody Molecule ZHER2:342

Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors

Phage display peptide probes for imaging early response to bevacizumab treatment